Newly uncovered DEA agreements confirm what MMJ BioPharma Cultivation has argued for years - that the agency's own rules make it impossible for any company to legally produce pharmaceutical grade cannabis for FDA authorized clinical research. WASHINGTON, D.C. / ACCESS Newswire / October 26, 2025 / A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed the DEA fatal flaw at the heart of America's cannabis research policy - one that proves MMJ BioPharma Cultivation's case and exposes why legitimate science has been paralyzed for nearly a decade. The Bureaucratic Catch-22 Under the terms of the DEA's own memorandum, licensees are required to perform highly restricted tasks: apply for quotas, send samples to DEA approved labs, provide advance harvest notices, follow DEA mandated packaging and storage procedures, and ultimately invoice the DEA for the very cannabis they grow.